Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSCT for CVID and PIRD
NCT07284641Phase 2Recruiting
- Sponsor
- Paul Szabolcs
- Start
- May 2026
- Primary completion
- May 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in common variable immunodeficiency (CVID) and primary immune regulatory disorder (PIRD), sponsored by Paul Szabolcs. Primary endpoint: Survival post-HSCT at 2 years. Started May 2026; status: recruiting.
02
Conditions
common variable immunodeficiency (CVID)primary immune regulatory disorder (PIRD)
Beyond the preview
Go deeper on NCT07284641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284641.